CareDx, Inc. (CDNA) shareholders
CDNANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 12/3033% above fair value
$77.88−1.93 (-2.42%)
Close on Nov 13, 2026Market cap $4.09BP/E 32.6Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
53M of 53M shares
Institutional holders
227
54 new, 13 sold out
Net institutional buying
2M
In Q2 2026
Insider trades, 12 months
0 buys · 36 sales
Net sold $18.42M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 4,664,092 | 9.00% | 13G (passive) amendment | Jun 30, 2026 |
| Bellevue Group AG Joint filing with Bellevue Asset Management (UK) Ltd. (5.80%) | 3,145,546 | 5.90% | 13G (passive) amendment | Nov 14, 2024 |
| State Street Corporation | 2,623,064 | 5.10% | 13G (passive) | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CDNA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,814,709 | 9.16% | $137.22M | +292,613 | 0.00% |
| State Street Corp | 2,468,858 | 4.70% | $70.36M | −291,527 | 0.00% |
| Vanguard Capital Management LLC | 2,197,475 | 4.18% | $62.63M | +37,018 | 0.00% |
| Deerfield Management Company, L.P. (Series C) | 1,997,618 | 3.80% | $56.93M | −193,382 | 0.59% |
| ARK Investment Management LLC | 1,953,531 | 3.72% | $55.68M | −274,025 | 0.36% |
| Boston Partners | 1,937,601 | 3.69% | $55.22M | +54,067 | 0.05% |
| Bamco Inc /Ny/ | 1,937,326 | 3.69% | $55.21M | −1,399,083 | 0.08% |
| Gagnon Securities LLC | 1,770,735 | 3.37% | $50.47M | +8,861 | 9.73% |
| Chevy Chase Trust Holdings, LLC | 1,437,416 | 2.74% | $40.97M | −66,659 | 0.11% |
| Geode Capital Management, LLC | 1,328,037 | 2.53% | $37.86M | +73,923 | 0.00% |
| Ophir Asset Management Pty Ltd | 1,264,809 | 2.41% | $36.05M | +276,758 | 2.96% |
| Renaissance Technologies LLC | 1,242,959 | 2.37% | $35.42M | +58,561 | 0.05% |
| Braidwell LP | 1,220,602 | 2.32% | $34.79M | −952,544 | 1.29% |
| First Eagle Investment Management, LLC | 1,196,994 | 2.28% | $34.11M | +621,629 | 0.03% |
| Sumitomo Mitsui Trust Holdings, Inc. | 1,191,630 | 2.27% | $33.96M | −283,496 | 0.02% |
| Blue Water Life Science Advisors, LP | 1,190,000 | 2.26% | $33.92M | +255,000 | 21.36% |
| Nikko Asset Management Americas, Inc. | 1,188,075 | 2.26% | $33.85M | −287,051 | 0.44% |
| Dimensional Fund Advisors LP | 1,181,077 | 2.25% | $33.66M | −280,837 | 0.01% |
| D. E. Shaw & Co., Inc. | 1,137,660 | 2.17% | $32.42M | +262,752 | 0.02% |
| Jacobs Levy Equity Management, Inc | 995,669 | 1.89% | $28.38M | +131,201 | 0.10% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 227 | 53M | 100.0% | 54 / 77 | 68 / 13 | 7M | 6M |
| Q1 2026 | 191 | 53M | 100.0% | 26 / 74 | 59 / 31 | 9M | 5M |
| Q4 2025 | 200 | 52M | 99.3% | 41 / 63 | 64 / 27 | 6M | 7M |
| Q3 2025 | 187 | 54M | 100.0% | 35 / 63 | 63 / 45 | 12M | 13M |
| Q2 2025 | 197 | 54M | 100.0% | 25 / 67 | 69 / 45 | 5M | 7M |
| Q1 2025 | 218 | 56M | 100.0% | 40 / 64 | 81 / 28 | 9M | 6M |
| Q4 2024 | 210 | 53M | 100.0% | 42 / 89 | 50 / 43 | 9M | 7M |
| Q3 2024 | 215 | 52M | 98.3% | 72 / 64 | 58 / 9 | 15M | 12M |
| Q2 2024 | 154 | 54M | 100.0% | 33 / 50 | 58 / 25 | 6M | 10M |
| Q1 2024 | 146 | 57M | 100.0% | 17 / 47 | 60 / 18 | 7M | 5M |
| Q4 2023 | 147 | 55M | 100.0% | 26 / 47 | 54 / 28 | 8M | 8M |
| Q3 2023 | 150 | 56M | 100.0% | 17 / 51 | 62 / 21 | 4M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
223 funds held CDNA in Q2 2026, 56% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CDNA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,554,868 | 2.96% | $44.31M | 0.00% | Jun 30, 2026 |
| ARK Genomic Revolution ETF | 1,531,579 | 2.91% | $66.95M | 4.30% | Jul 31, 2026 |
| Baron Discovery Fund | 1,373,550 | 2.61% | $39.15M | 2.14% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,341,622 | 2.55% | $38.24M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 1,143,357 | 2.18% | $32.59M | 0.30% | Jun 30, 2026 |
| Column Small Cap Select Fund | 651,753 | 1.24% | $14.87M | 0.79% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 588,494 | 1.12% | $16.77M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 560,759 | 1.07% | $24.51M | 0.07% | Jul 31, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 493,746 | 0.94% | $11.27M | 0.01% | May 31, 2026 |
| First Eagle Small Cap Opportunity Fund | 485,136 | 0.92% | $21.21M | 0.73% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 473,411 | 0.90% | $13.49M | 0.09% | Jun 30, 2026 |
| iShares Biotechnology ETF | 329,015 | 0.63% | $9.38M | 0.10% | Jun 30, 2026 |
| Invesco Biotechnology & Genome ETF | 325,179 | 0.62% | $14.21M | 5.04% | Jul 31, 2026 |
| JNL Multi-Manager Small Cap Growth Fund | 289,337 | 0.55% | $8.25M | 0.32% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 266,600 | 0.51% | $6.08M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John Walter Hanna JR | President and CEO, Director | 644,937 | 1.23% | Oct 5, 2026 |
| Jeffrey Adam Novack | Secretary and General Counsel | 96,604 | 0.18% | Nov 12, 2026 |
| Keith Kennedy | CFO & COO | 199,147 | 0.38% | Nov 9, 2026 |
| Jessica Meng | Chief Commercial Officer | 158,980 | 0.30% | Oct 5, 2026 |
| Nathan Smith | Chief Financial Officer | 75,000 | 0.14% | Feb 4, 2026 |
| Abhishek Jain | Chief Financial Officer | 319,725 | 0.61% | Aug 5, 2025 |
| George Bickerstaff | Director | 149,061 | 0.28% | Nov 12, 2026 |
| Fred E. Cohen | Director | 140,060 | 0.27% | Nov 4, 2026 |
| Michael Goldberg | Director | 153,371 | 0.29% | Oct 5, 2026 |
| Christine Cournoyer | Director | 42,943 | 0.08% | Aug 6, 2026 |
| Hannah Valantine | Director | 36,786 | 0.07% | Jul 17, 2026 |
| Richard Bryan Riggsbee | Director | 39,312 | 0.07% | Jun 16, 2026 |
| Suresh Gunasekaran | Director | 37,248 | 0.07% | Jun 16, 2026 |
| Arthur A. Torres | Director | 38,665 | 0.07% | May 18, 2026 |
| Peter Maag | Director | 309,846 | 0.59% | Jul 10, 2025 |
| William A. Hagstrom | Director | 73,370 | 0.14% | Jun 13, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jeffrey Adam Novack Secretary and General Counsel | Nov 10, 2026 | Sale(10b5-1 plan) | −900 | $83.33 | $75.00K | 96,604 |
| Jeffrey Adam Novack Secretary and General Counsel | Nov 10, 2026 | Sale(10b5-1 plan) | −200 | $81.05 | $16.21K | 97,504 |
| Jeffrey Adam Novack Secretary and General Counsel | Nov 10, 2026 | Sale(10b5-1 plan) | −2,996 | $80.47 | $241.09K | 97,704 |
| George Bickerstaff Director | Nov 10, 2026 | Option exercise | +15,000 | $14.74 | $221.10K | 149,061 |
| Jeffrey Adam Novack Secretary and General Counsel | Nov 6, 2026 | Tax withholding | −1,505 | $78.56 | $118.23K | 100,700 |
| Keith Kennedy CFO & COO | Nov 5, 2026 | Sale(10b5-1 plan) | −600 | $83.60 | $50.16K | 199,147 |
| Keith Kennedy CFO & COO | Nov 5, 2026 | Sale(10b5-1 plan) | −300 | $82.08 | $24.62K | 199,747 |
| Keith Kennedy CFO & COO | Nov 5, 2026 | Sale(10b5-1 plan) | −2,710 | $81.40 | $220.61K | 200,047 |
| Keith Kennedy CFO & COO | Nov 5, 2026 | Sale(10b5-1 plan) | −3,403 | $80.38 | $273.53K | 202,757 |
| Keith Kennedy CFO & COO | Nov 5, 2026 | Sale(10b5-1 plan) | −7,415 | $79.49 | $589.38K | 206,160 |
| Keith Kennedy CFO & COO | Nov 5, 2026 | Sale(10b5-1 plan) | −6,897 | $78.59 | $542.02K | 213,575 |
| Keith Kennedy CFO & COO | Nov 5, 2026 | Sale(10b5-1 plan) | −12,380 | $77.42 | $958.44K | 220,472 |
| Keith Kennedy CFO & COO | Nov 5, 2026 | Sale(10b5-1 plan) | −28,256 | $76.55 | $2.16M | 232,852 |
| Keith Kennedy CFO & COO | Nov 5, 2026 | Option exercise | +52,422 | $29.43 | $1.54M | 261,108 |
| Fred E. Cohen Director | Nov 3, 2026 | Gift | −25,000 | – | – | 140,060 |
| Jeffrey Adam Novack Secretary and General Counsel | Nov 1, 2026 | Tax withholding | −2,873 | $85.88 | $246.73K | 102,205 |
| Michael Goldberg Director | Oct 2, 2026 | Award | +588 | – | – | 62,326 |
| Jessica Meng Chief Commercial Officer | Oct 1, 2026 | Tax withholding | −2,619 | $66.23 | $173.46K | 158,980 |
| Jeffrey Adam Novack Secretary and General Counsel | Oct 1, 2026 | Tax withholding | −997 | $66.23 | $66.03K | 105,078 |
| John Walter Hanna JR President and CEO, Director | Oct 1, 2026 | Tax withholding | −8,511 | $66.23 | $563.68K | 644,937 |
| Keith Kennedy CFO & COO | Oct 1, 2026 | Tax withholding | −3,018 | $66.23 | $199.88K | 208,686 |
| Jessica Meng Chief Commercial Officer | Sep 12, 2026 | Tax withholding | −6,688 | $52.37 | $350.25K | 161,599 |
| Keith Kennedy CFO & COO | Sep 12, 2026 | Tax withholding | −8,220 | $52.37 | $430.48K | 211,704 |
| Jeffrey Adam Novack Secretary and General Counsel | Aug 5, 2026 | Sale(10b5-1 plan) | −500 | $46.75 | $23.38K | 106,075 |
| Jeffrey Adam Novack Secretary and General Counsel | Aug 5, 2026 | Sale(10b5-1 plan) | −2,188 | $46.15 | $100.98K | 106,575 |
| George Bickerstaff Director | Aug 5, 2026 | Sale | −20,000 | $46.29 | $925.80K | 134,061 |
| Christine Cournoyer Director | Aug 4, 2026 | Sale(10b5-1 plan) | −16,000 | $46.94 | $751.04K | 42,943 |
| Michael Goldberg Director | Aug 4, 2026 | Sale | −44,700 | $47.06 | $2.10M | 61,738 |
| Jeffrey Adam Novack Secretary and General Counsel | Aug 1, 2026 | Tax withholding | −2,872 | $47.85 | $137.43K | 108,763 |
| John Walter Hanna JR President and CEO, Director | Jul 16, 2026 | Sale(10b5-1 plan) | −50,000 | $36.11 | $1.81M | 721,448 |
| John Walter Hanna JR President and CEO, Director | Jul 16, 2026 | Option exercise | +118,000 | $8.20 | $967.60K | 771,448 |
| John Walter Hanna JR President and CEO, Director | Jul 16, 2026 | Sale(10b5-1 plan) | −68,000 | $39.01 | $2.65M | 653,448 |
| Hannah Valantine Director | Jul 16, 2026 | Sale(10b5-1 plan) | −28,679 | $36.14 | $1.04M | 36,786 |
| Hannah Valantine Director | Jul 16, 2026 | Option exercise | +16,048 | $14.19 | $227.72K | 60,340 |
| Hannah Valantine Director | Jul 16, 2026 | Option exercise | +5,125 | $7.96 | $40.80K | 65,465 |
| Hannah Valantine Director | Jul 16, 2026 | Sale(10b5-1 plan) | −100 | $36.55 | $3.65K | 36,686 |
| Hannah Valantine Director | Jul 16, 2026 | Option exercise | +7,606 | $20.56 | $156.38K | 44,292 |
| Michael Goldberg Director | Jul 2, 2026 | Award | +1,746 | – | – | 106,438 |
| John Walter Hanna JR President and CEO, Director | Jul 1, 2026 | Tax withholding | −8,511 | $29.25 | $248.95K | 653,448 |
| Keith Kennedy CFO & COO | Jul 1, 2026 | Tax withholding | −2,930 | $29.25 | $85.70K | 219,924 |
| Jeffrey Adam Novack Secretary and General Counsel | Jul 1, 2026 | Tax withholding | −997 | $29.25 | $29.16K | 111,635 |
| Jessica Meng Chief Commercial Officer | Jul 1, 2026 | Tax withholding | −2,411 | $29.25 | $70.52K | 168,287 |
| John Walter Hanna JR President and CEO, Director | Jun 29, 2026 | Sale(10b5-1 plan) | −39,900 | $29.24 | $1.17M | 661,959 |
| John Walter Hanna JR President and CEO, Director | Jun 29, 2026 | Option exercise | +39,900 | $8.20 | $327.18K | 701,859 |
| John Walter Hanna JR President and CEO, Director | Jun 26, 2026 | Sale(10b5-1 plan) | −100 | $29.00 | $2.90K | 661,959 |
| John Walter Hanna JR President and CEO, Director | Jun 26, 2026 | Option exercise | +100 | $8.20 | $820 | 662,059 |
| John Walter Hanna JR President and CEO, Director | Jun 15, 2026 | Option exercise | +15,676 | $8.20 | $128.54K | 661,959 |
| John Walter Hanna JR President and CEO, Director | Jun 15, 2026 | Sale(10b5-1 plan) | −17,683 | $24.03 | $424.92K | 631,959 |
| Hannah Valantine Director | Jun 15, 2026 | Sale(10b5-1 plan) | −12,103 | $23.11 | $279.70K | 36,686 |
| Christine Cournoyer Director | Jun 12, 2026 | Award | +9,795 | – | – | 58,943 |
| Michael Goldberg Director | Jun 12, 2026 | Award | +9,795 | – | – | 195,737 |
| George Bickerstaff Director | Jun 12, 2026 | Award | +9,795 | – | – | 154,061 |
| Richard Bryan Riggsbee Director | Jun 12, 2026 | Award | +9,795 | – | – | 39,312 |
| Fred E. Cohen Director | Jun 12, 2026 | Award | +9,795 | – | – | 165,060 |
| Suresh Gunasekaran Director | Jun 12, 2026 | Award | +9,795 | – | – | 37,248 |
| Hannah Valantine Director | Jun 12, 2026 | Award | +9,795 | – | – | 48,789 |
| John Walter Hanna JR President and CEO, Director | Jun 11, 2026 | Option exercise | +13,618 | $8.20 | $111.67K | 646,283 |
| John Walter Hanna JR President and CEO, Director | Jun 11, 2026 | Sale(10b5-1 plan) | −21,998 | $24.02 | $528.39K | 649,642 |
| Jeffrey Adam Novack Secretary and General Counsel | Jun 6, 2026 | Tax withholding | −1,292 | $21.95 | $28.36K | 112,632 |
| John Walter Hanna JR President and CEO, Director | Jun 4, 2026 | Option exercise | +706 | $8.20 | $5.79K | 632,665 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
14.37%
7M shares short
Days to cover
5.3
At 1M shares a day
Change since last report
+7.0%
From 7M shares
Short volume, 20 days
49.1%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of CareDx's stock actually held short. Settlement fails (shares not delivered on time) peaked at 11,711 shares on Aug 26, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jeffrey Adam Novack Officer | Nov 10, 2026 | 4,096 | $345.78K | Nov 10, 2026 | Restricted Stock Units |
| Keith Kennedy Officer | Nov 5, 2026 | 79,243 | $6.80M | Nov 5, 2026 | Exercise of Stock Options |
| Peter Maag Director | Aug 17, 2026 | 9,122 | $423.09K | Aug 17, 2026 | Restricted Stock |
| Peter Maag Director | Aug 14, 2026 | 7,000 | $317.11K | Aug 14, 2026 | Restricted Stock |
| Peter Maag Director | Aug 13, 2026 | 7,000 | $329.51K | Aug 13, 2026 | Restricted Stock |
| Peter Maag Director | Aug 12, 2026 | 7,000 | $328.24K | Aug 12, 2026 | Restricted Stock |
| Peter Maag Director | Aug 11, 2026 | 7,000 | $333.85K | Aug 11, 2026 | Restricted Stock |
| Arthur A. Torres Director | Aug 10, 2026 | 4,200 | $200.48K | Aug 10, 2026 | Restricted Stock |
| Peter Maag Director | Aug 10, 2026 | 6,902 | $328.95K | Aug 10, 2026 | Restricted Stock |
| Peter Maag Director | Aug 7, 2026 | 27,332 | $1.25M | Aug 7, 2026 | Stock Option Exercise |
| Peter Maag Director | Aug 5, 2026 | 46,963 | $2.18M | Aug 5, 2026 | Restricted Stock |
| Jeffrey Adam Novack Officer | Aug 5, 2026 | 2,688 | $126.58K | Aug 5, 2026 | Restricted Stock Units |
| George Bickerstaff Director | Aug 5, 2026 | 20,000 | $925.70K | Aug 5, 2026 | Compensation for Past Services |
| Christine Cournoyer Director | Aug 4, 2026 | 16,000 | $753.44K | Aug 4, 2026 | Acquired as compensation -- Restricted Stock Units |
| Christine Cournoyer Director | Aug 4, 2026 | 31,943 | $1.52M | Aug 4, 2026 | Stock Option Exercise |
See a number that looks wrong?